Graves Ophthalmopathy Clinical Trials

10 recruitingLast updated: May 13, 2026

There are 10 actively recruiting graves ophthalmopathy clinical trials across 5 countries. Studies span Not Applicable, Phase 2, Phase 3, Early Phase 1, Phase 4. Top locations include Bethesda, Maryland, United States, Elâzığ, Elaziğ, Turkey (Türkiye), Gothenburg, Sweden. Updated daily from ClinicalTrials.gov.


Graves Ophthalmopathy Trials at a Glance

10 actively recruiting trials for graves ophthalmopathy are listed on ClinicalTrialsFinder across 6 cities in 5 countries. The largest study group is Not Applicable with 2 trials, with the heaviest enrollment activity in Bethesda, Elâzığ, and Gothenburg. Lead sponsors running graves ophthalmopathy studies include Johns Hopkins University, Lund University, and Elazıg Fethi Sekin Sehir Hastanesi.

Browse graves ophthalmopathy trials by phase

Treatments under study

About Graves Ophthalmopathy Clinical Trials

Looking for clinical trials for Graves Ophthalmopathy? There are currently 10 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Graves Ophthalmopathy trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Graves Ophthalmopathy clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 110 of 10 trials

Recruiting
Phase 2

Tofacitinib for Glucocorticoid-Resistant Moderate-to-Severe Thyroid Eye Disease

Graves OrbitopathyGraves OphthalmopathyThyroid Eye Disease (TED)
The First Affiliated Hospital of Xiamen University8 enrolled1 locationNCT07547930
Recruiting
Not Applicable

Statin and Vitamin D Treatment in Patients With Thyroid Eye Disease

Graves OphthalmopathyThyroid Eye Disease (TED)
Taipei Veterans General Hospital, Taiwan120 enrolled1 locationNCT07400757
Recruiting

Systemic Inflammation, Thyroid Autoimmunity and Neuroretinal Changes in Graves Disease

Graves DiseaseGraves Ophthalmopathy
Elazıg Fethi Sekin Sehir Hastanesi100 enrolled1 locationNCT07480720
Recruiting

Exploring Immunological Markers Associated With Mental Fatigue in Graves' Disease

Graves DiseaseThyroid DiseasesAutoimmune Diseases+2 more
Vastra Gotaland Region180 enrolled1 locationNCT05678374
Recruiting
Early Phase 1

Bimatoprost as a Treatment for Graves' Orbitopathy

Graves Ophthalmopathy
Johns Hopkins University3 enrolled1 locationNCT03708627
Recruiting
Phase 2Phase 3

Extension Study of Two Doses of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED)

Thyroid DiseasesEndocrine System DiseasesThyroid Eye Disease+9 more
Sling Therapeutics, Inc.75 enrolled2 locationsNCT06112340
Recruiting
Phase 4

Hydroxychloroquine in Mild Graves' Orbitopathy

Graves Ophthalmopathy
National Taiwan University Hospital108 enrolled2 locationsNCT05126147
Recruiting
Phase 3

Treatment of Graves´ophthalmopathy with Simvastatin (GO-S)

Thyroid Associated OphthalmopathyGraves OphthalmopathyThyroid Associated Orbitopathy
Lund University80 enrolled1 locationNCT03131726
Recruiting
Not Applicable

Modified Orbital Decompression in the Treatment of Moderate-to-severe Grave's Ophthalmopathy

SurgeryGraves Ophthalmopathy
Sun Yat-sen University50 enrolled1 locationNCT06588764
Recruiting

The Effect of Teprotumumab on Thyroid Eye Disease and Thyroid Dysfunction

Graves DiseaseThyroid Eye DiseaseGraves Ophthalmopathy
Walter Reed National Military Medical Center100 enrolled1 locationNCT06275373